Posted by Michael Wonder on 20 Sep 2023
Tyenne, Fresenius Kabi’s tocilizumab biosimilar, receives European Commission approval
19 September 2023 - Tyenne is the first tocilizumab biosimilar approved by the European Commission.
Fresenius Kabi announced today that the European Commission granted marketing authorisation for its tocilizumab biosimilar Tyenne, referencing RoActemra (tocilizumab), valid for all member states of the European Union.
